Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Ardea Biosciences, Inc./DE | exhibit1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | May 30, 2012 |
Ardea Biosciences, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 001-33734 | 94-3200380 |
|
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 4939 Directors Place, San Diego, California | 92121 | |
|
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 858-652-6500 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On May 30, 2012, Ardea Biosciences, Inc. (the "Company") issued the press release that is furnished as Exhibit 99.1 to this Current Report on Form 8-K and that is incorporated by reference into this Item announcing that the Company has earned a $7.5 million milestone payment from Bayer HealthCare under the terms of their April 2009 global license agreement to develop and commercialize the Company's mitogen-activated ERK kinase inhibitor compounds for cancer and other indications.
Item 9.01 Financial Statements and Exhibits.
Exhibit Number/ Exhibit Description
99.1/ Press Release dated May 30, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Ardea Biosciences, Inc. | ||||
| May 30, 2012 | By: |
/s/ Christian Waage
|
||
|
|
||||
| Name: Christian Waage | ||||
| Title: General Counsel | ||||
Exhibit Index
| Exhibit No. | Description | |
|
|
|
|
|
99.1
|
Press Release dated May 30, 2012. |